1.	Phase II Randomized Study of Immunization With Carcinoembryonic Antigen (CEA) Peptide 1-6D Emulsified in Montanide ISA-51 Versus Dissolved in Sargramostim (GM-CSF) in HLA-A2+ Patients With CEA-Producing Adenocarcinomas of Gastrointestinal Tract Origin Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UTMB-00-297, NCI-931, NCT00012246, 931
2.	Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 12095B, NCT00203892
3.	Phase I Study of Vaccination With Autologous Dendritic Cells Pulsed With Carcinoembryonic Antigen Peptide 1-6D (CAP 1-6D) and CMV pp65 Peptide in Patients With Refractory Stage IV CEA-Expressing Malignancies Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: DUMC-4180-03-10R1, NCI-5910, NCT00057915, 5910